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In 1997 a mutation in the a-synuclein (SNCA) gene was associated with familial autosomal dominant Parkinson’s disease (PD).
Sincethen,severalloci(PARK1-15)andgeneshavebeenlinkedtofamilialformsofthedisease.Thereisnowsuﬃcientevidencethat
sixofthesofaridentiﬁedgenesatPARKloci(a-synuclein,leucine-richrepeatkinase2,parkin,PTEN-inducedputativekinase1,DJ-1,
and ATP13A2) cause inherited forms of typical PD or parkinsonian syndromes. Other genes at non-PARK loci (MAPT, SCA1,
S C A 2 ,s p a t a c s i n ,P O L G 1 ) cause syndromes with parkinsonism as one of the symptoms. The majority of PD cases are however
sporadic “idiopathic” forms, and the recent application of genome-wide screening revealed almost 20 genes that might contribute
to disease risk. In addition, increasing evidence suggests that epigenetic mechanisms, such as DNA methylation, histone modiﬁca-
tions, and small RNA-mediated mechanisms, could regulate the expression of PD-related genes.
1. Geneticsof Parkinson’s Disease(PD)
Parkinson’s disease (PD) is a common neurodegenerative
disorder aﬀecting 1-2% of the population over the age of 65
years and reaching a prevalence of almost 4% in those aged
above 85 years. Resting tremor, rigidity, bradykinesia, and
postural instability are the main clinical symptoms of the
disease often accompanied by nonmotor symptoms includ-
ingautonomicinsuﬃciency,cognitiveimpairment,andsleep
disorders. The brain of PD individuals is pathologically char-
acterizedbyaprogressiveandprofoundlossofneuromelanin
containing dopaminergic neurons in the substantia nigra
with the presence of eosinophilic, intracytoplasmic inclu-
sions termed as Lewy bodies (LBs: containing aggregates of
α-synucleinaswellasothersubstances),andLewyneuritesin
surviving neurons. Unfortunately, only some improvements
of the symptoms are oﬀered by current treatments based on
levodopaanddopaminergictherapy,butthereisnocurrently
available treatment to arrest the progression of the disease
[1].
A familial history of PD is shown in approximately 20%
of the cases, and in a minority of them the disease follows
Mendelian inheritance patterns. Studies in PD families led
to the identiﬁcation of 15 PD loci (PARK1-15), and 11
genes for PARK loci have so far been described (Table 1).
Although follow-up genetic studies have been inconsistent
for some of them or conclusive data are still pending, there is
evidence that ﬁve of those genes (a-synuclein, parkin, PTEN-
i n d u c e dp u t a t i v ek i n a s e1 ,D J - 1 ,and leucine-rich repeat kinase
2) cause typical PD [2], and mutations of ATP13A2 (PARK9)
cause Kufor-Rakeb disease, an autosomal recessive parkin-
sonism with many other features, including pyramidal tract
dysfunction, supranuclear gaze paresis, and dementia [3].
The vast majority of PD cases are however sporadic (idio-
pathic) forms, likely resulting from a combination of poly-
genic inheritance, environmental exposures, and complex
gene-environment interactions superimposed on slow and
sustained neuronal dysfunction due to aging [4]. Therefore,
linkage analyses in PD families have been paralleled by sever-
al hundreds of genetic association studies in order to identify
genetic variants able to modify the individual risk to develop
idiopathic forms of the disease. These studies have been
conducted by either the candidate gene approach or, more
recently, by means of genome-wide screenings, that is, ge-
nome-wideassociationstudies(GWASs).Thegeneticscreen-
ing has been successful with a common high-risk locus2 The Scientiﬁc World Journal
Table 1: Loci and genes associated with familial PD.
Designation Locus Gene Inheritance∗ Refs
Validated loci
PARK1/PARK4 4q21 SNCA AD [5–16]
PARK8 12q12 LRRK2 AD
PARK2 6q25.2–q27 PARK AR
PARK6 1p35-36 PINK1 AR
PARK7 1p36 DJ-1 AR
PARK9 1p36 ATP13A2 AR
Other loci
PARK3 2p13 Unknown AD [17–23]
PARK5 4p14 UCH-L1 AD
PARK8 12q12 LRRK2 AD
PARK10 1p32 Unknown Not clear
PARK11 2q36-37 GIGYF2 AD
PARK12 Xq21-q25 Unknown X-linked
PARK13 2p12 OMI/ HTRA2 AD
PARK 14 22q13.1 PLA2G6 AR
PARK 15 22q11.2-qter FBXO7 AR
∗AD: autosomal dominant; AR: autosomal recessive.
identiﬁed (GBA) ,a n dm a n yc o m m o nl o w - r i s kl o c i( SNCA,
MAPT, LRRK2) were recently elucidated [24]. Moreover, the
application of GWAS technology and the creation of inter-
national collaborative groups sharing samples and results are
continuously revealing novel variants that could contribute
to disease risk [25].
Thelastfewyearshaveseenthegrowingofevidencedeal-
ing with the possible contribution of epigenetic modiﬁca-
tions to human diseases, including among others neurode-
generative ones [26–28]. The term “epigenetics” is used to
describe those mechanisms able to modify the expression
levels of selected genes without necessarily altering their
DNA sequence, including DNA methylation, histone tail
modiﬁcations, and chromatin remodeling, as well as mecha-
nisms mediated by small RNA molecules. Epigenetic mod-
iﬁcations are often environmentally induced, and tissue-
speciﬁc phenomena that can have similar eﬀects to those of
pathogenic mutations or functional polymorphisms, since
they are able to silence, increase or reduce the expression of a
selected gene in a given tissue [29]. This paper aims at des-
cribingthecurrentknowledgeongeneticalterationsandepi-
geneticmodiﬁcationslikelycontributingtoPDpathogenesis.
2. FamilialParkinson’s Disease
There is suﬃcient evidence that six of the so far identiﬁed
genes at PARK loci cause inherited forms of typical PD or
parkinsonian syndromes. Only two of them (a-synuclein and
leucine-rich repeat kinase 2) cause autosomal dominant
forms, whilst the other four (parkin, PTEN-induced putative
kinase 1, DJ-1, and ATP13A2) are inherited in an autosomal
Table 2: Additional genes causing parkinsonism.
Gene Disease Refs
MAPT Frontotemporal dementia with
parkinsonism linked to chromosome 17 [30–38]
ATXN2 Spinocerebellar ataxia type 2 and
parkinsonism
ATXN3 Spinocerebellar ataxia type 3 and
parkinsonism
SPG11 Hereditary spastic paraplegia and
parkinsonism
POLG1 Mitochondrial parkinsonism
recessive fashion. Additional PARK loci have been so far
described (Table 1), pending identiﬁcation of a causative
gene or conﬁrmation/validation of the candidate one. More-
over, in addition to the genes mapped to the sequentially
numbered PARK1-15 loci, other genes, such as MAPT,
ATXN2, ATXN3, spatacsin,a n dPOLG1 (Table 2), are known
to cause syndromes that can clinically manifest with parkin-
sonism as one of the symptoms [24].
2.1. Autosomal Dominant PD
2.1.1. α-Synuclein (SNCA): PARK1 and PARK4. In 1997
Polymeropoulos et al. [5]describedamutationinthea-synu-
clein gene (SNCA) on 4q21 (PARK1), causing an A53T
amino acidic substitution and segregating with PD in an
Italian kindred and 3 unrelated families of Greek origin [5].
TwoadditionalSNCAmutations(A30PandE46K)weresub-
sequently described in other families with autosomal domi-
nant PD [6, 7]. Moreover, a triplication of the a-synuclein
gene (PARK4) was observed in a large family as causative of
PD [8], and other PD families have been described with a-
synuclein gene duplication and a disease course less severe of
that observed in PARK4 carriers, suggesting the existence of
ag e n ed o s a g ee ﬀect [9]. Although SNCA has been the ﬁrst
PD gene identiﬁed, SNCA mutations and multiplications are
both extremely rare causes of familial autosomal dominant
PD [2]. α-Synuclein is expressed throughout the mam-
malian brain particularly in presynaptic nerve terminals, and
mutated α-synuclein has an increased tendency to form ag-
gregates critical to Lewy bodies (LBs) formation. These ﬁ-
brillar aggregates are the major component of LBs in both
familial and idiopathic PD, and aggregation of α-synuclein
is thought to be a key event in dopaminergic neuronal cell
death. The function of α-synuclein under normal physiolog-
ical conditions is not yet completely clear, although there is
evidence that implicates SNCA in neurotransmitter release
and vesicle turnover at the presynaptic terminals [39, 40].
2.1.2. Leucine-Rich Repeat Kinase 2 (LRRK2): PARK8. The
LRRK2 gene was mapped on the PARK8 locus in 12q12 and
was the second gene linked to autosomal dominant PD [10,
11]. Over 100 LRRK2 mutations have been so far described
in PD families and sporadic cases, but the pathogenic role of
many of them has not yet been proven (a complete list can beThe Scientiﬁc World Journal 3
found at: http://www.molgen.ua.ac.be/PDmutDB/). LRRK2
encodesaproteinnameddardarin(fromdardara,theBasque
word for tremor) which contains several domains including
the catalytic domain of a tyrosine kinase. The presence of a
kinase domain suggests a role for dardarin in signaling cas-
cades, likely relating to cytoskeletal dynamics [24]. The most
prevalent LRRK2 mutation is a G2019S missense mutation
occurringin1-2% ofPDpatients ofEuropeanorigin, 20% of
Ashkenazi Jewish patients, and approximately 40% of Arab
Berbers with PD. The Arg1441 codon is another frequent
hotspot of LRRK2 pathogenic mutations [2].
2.2. Autosomal Recessive PD
2.2.1. Parkin: PARK2. Autosomal recessive juvenile parkin-
sonism (AR-JP) is caused by mutations of the parkin gene
on chromosome 6q25.2–q27 (PARK2) [12]. The disease is
characterized by early onset and a marked response to lev-
odopa treatment and diﬀers from idiopathic PD in that there
is usually no LBs formation. Over 100 mutations in parkin,
including missense mutations and exonic deletions and
insertions,havebeenobservedinPDfamilies[41].Parkinisa
ubiquitin E3 ligase preparing target proteins for their degra-
dation mediated by the ubiquitin-proteosomal system [42].
Moreover, parkin is involved in mitochondrial maintenance,
repair of mitochondrial DNA damage, might contribute to
mitochondrial cytochrome c release, and induce subsequent
autophagy of dysfunctional mitochondria [43–47].
2.2.2. PTEN-Induced Putative Kinase 1 Gene (PINK-1):
PARK6. Mutations in the PTEN-induced putative kinase 1
(PINK-1) gene on chromosome 1p35-36 (PARK6) have been
linked to autosomal recessive early-onset PD [13]. Several
diﬀerentPINK1mutations,primarilymissenseandnonsense
ones, have been identiﬁed in PD families worldwide and
cause mitochondrial deﬁcits contributing to PD pathogen-
esis (http://www.molgen.ua.ac.be/PDmutDB/). PINK1 is a
kinasewithanN-terminalmitochondrialtargetingsequence,
provides protection against mitochondrial dysfunction, and
regulates mitochondrial morphology via ﬁssion/fusion ma-
chinery. PINK1 also acts upstream of parkin in a common
pathway in the maintenance of mitochondrial quality via
autophagy [48].
2.2.3. DJ-1: PARK7. Mutations in the DJ-1 gene on 1p36
(PARK7), including exonic deletions and point mutations,
have been associated with a monogenic early-onset autoso-
mal recessive form of parkinsonism characterized by slow
progression and response to levodopa [14, 15]. A complete
list of DJ-1 mutations can be found at the PD mutation
database (http://www.molgen.ua.ac.be/PDmutDB/). DJ-1 is
a mitochondrial protein involved in the protection against
oxidative stress and forms a complex with parkin and
PINK1 to promote ubiquitination and degradation of parkin
substrates, including parkin itself [49]. Recent evidence indi-
cates that DJ-1 works in parallel to the PINK1/parkin path-
way to maintain mitochondrial function in the presence of
an oxidative environment [50].
2.2.4. ATP13A2 Gene: PARK9. Clinical features similar to
those of idiopathic PD and pallydopyramidal syndrome, in-
cluding parkinsonism, pyramidal tract dysfunction, supra-
nuclear gaze paresis, and dementia, were observed in a Jor-
danian family. The pattern of transmission was autosomal
recessive, and a region of linkage was identiﬁed on chro-
mosome 1p36 (PARK9) [16]. The causative gene underlying
PARK9 was then identiﬁed as the ATP13A2 gene encoding a
lysosomal 5 P-type ATPase [3] likely involved in the regula-
tion of intracellular manganese homeostasis [51].
2.3. Additional PARK Loci. Additional putative PARK loci
include: (1) a locus on 2p13, denoted as PARK3 but with no
causative gene yet identiﬁed; (2) the UCH-L1 gene on 4p14
(PARK5) coding for a protein that possesses both a hydrolase
activity to generate the ubiquitin monomer and a ligase acti-
vity to link ubiquitin molecules to tag proteins for disposal;
(3) a locus on 1p32, denoted as PARK10 but with no causa-
tive gene yet identiﬁed; (4) the GYGYF2 gene on 2q36-37
(PARK11), encoding a protein that could participate in the
regulation of signaling at endosomes; (5) a locus on Xq21-
q25, denoted as PARK12 and showing X-linked inheritance,
but still pending characterization of the causative gene; (6)
the OMI/HTRA2 gene on chromosome 2p12 (PARK 13)
coding for a nuclear-encoded serine protease localized in the
intermembrane space of the mitochondria and involved in
mediating caspase-dependent and caspase-independent cel-
lular death; (7) the PLA2G6 gene on chromosome 22q13.1
(PARK14) encoding a calcium-independent group VI phos-
pholipaseA2;(8)theFBXO7 geneon22q11.2-qter(PARK15)
encoding for a member of the F-box family of proteins, all of
which may have a role in the ubiquitin-proteasome protein-
degradation pathway [17–23].
2.4. Other Loci. Parkinsonism is often observed as one of the
symptoms in other monogenic diseases (Table 2). For ex-
ample, the MAPT gene encodes for the microtubule-asso-
ciated protein tau, a protein that binds to microtubules and
is primarily involved in the organization and integrity of
the cytoskeleton. Hyperphosphorylated tau forms neuroﬁb-
rillary tangles in Alzheimer’s disease brains, and mutations
of MAPT causefrontotemporaldementia withparkinsonism
linkedtochromosome17(FTDP-17)[30,31].Parkinsonism,
dystonia, and postural tremor are particularly prevalent in
spinocerebellar ataxias types 2 (SCA2) and 3 (SCA3). SCA2
can manifest either with a cerebellar syndrome or as Parkin-
son’s syndrome, and SCA3, also known as Machado-Joseph
disease (MJD), is the most common form of spinocerebellar
ataxia worldwide. The diseases are caused by abnormal CAG
trinucleotide repeat expansion of ataxin-2 (ATXN2)a n d
ataxin-3 (ATXN3) genes, respectively [32, 33]. Ataxin-2 is an
enzyme involved in RNA processing, whilstataxin-3 is a deu-
biquitinating enzyme involved in the ubiquitin-proteasome
system.Theparkinsonianphenotypeofbothdiseasesisoften
observed in Asians [34, 35]. Autosomal recessive hereditary
spastic paraplegia with thin corpus callosum (SPG11) is a
rare neurodegenerative disorder often caused by mutations
in the gene encoding for spatacsin at the SPG11 locus on4 The Scientiﬁc World Journal
chromosome 15q. Two patients, of Turkish descent, from the
same consanguineous family, were aﬀected with SPG11 in
association with unusual early-onset parkinsonism that oc-
curred during the very early stages of SPG11 in both patients
[36]. Additional evidence indicates that mutation of SPG11
is a rare cause of early-onset levodopa-responsive parkin-
sonism with pyramidal signs [37]. There is also indication
thatrearrangementsofthegenecodingforthemitochondrial
DNA polymerase gamma (POLG1), involved in the repair of
mitochondrial DNA, can directly cause parkinsonism [38].
3. SporadicParkinson’s Disease
Several hundreds of genetic association studies have been
performed in the last few decades by means of the candidate
gene approach in order to identify genetic risk factors for
non-Mendelian forms of PD.
The candidate gene was selected based on the knowledge
of its function in a pathway related to PD pathogenesis, and
only one single gene and one or a few polymorphisms were
usually investigated. More recently, those studies have been
replaced by GWAS where half a million or more polymor-
phisms are simultaneously investigated in large case-control
cohorts. GWASs are currently considered as the gold stan-
dard to ﬁnd loci at which common, normal genetic vari-
ability contributes to disease risk, and their introduction has
revolutionized our knowledge in the genetics of sporadic PD
[24].ThePDGenedatabase[52]isapublicandcontinuously
updateddatabasecollectingdatafromPDgeneticassociation
studies and GWAS. Accessed on October 2011, the database
contained information on 860 studies for a total of 909 can-
didate genes and 3434 polymorphisms within those genes. In
addition, data from GWAS and other large-scale studies were
available [52]. There is strong consensus from either GWAS
or updated meta-analyses of the literature that variants at
four loci (SNCA, MAPT, GBA and LRRK2) contribute to dis-
ease risk (Table 3). In addition, recent GWASs have revealed
novel putative PD risk loci to be conﬁrmed in future studies
[25], and the meta-analysis of the literature suggests that
several additional loci could contribute to disease risk [52]
(Table 3).
3.1.α-Synuclein(SNCA). Commonpolymorphismsofcaus-
ative PD genes have been frequently investigated as possible
risk factors for the idiopathic forms of the disease. Particu-
larly, genetic polymorphisms in the SNCA gene have been
consistently associated with PD risk in genetic association
studies and subsequently replicated in large-scale GWAS, in-
cluding a dinucleotide repeat sequence (Rep1) within the
promoter region and several single nucleotide polymor-
phisms (SNPs) at the 3 end of the gene, overall suggesting
that SNCA alleles associated with increased disease risk cor-
relate with higher α-synuclein expression, and pointing to
ag e n ed o s a g ee ﬀect [52–60]. Meta-analyses of those studies
revealedthatSNCAisalow-risklocusforidiopathicPD,with
odds ratios (ORs) ranging from 1.2 to 1.4 [52].
3.2. Leucine-Rich Repeat Kinase 2. Variants of LRRK2 have
been consistently associated with increased risk for sporadic
Table 3: Genes or loci associated with idiopathic PD.
Gene or locus Methodologies employed Refs
SNCA Large-scale association studies [25, 52–68]
LRRK2
MAPT Meta-analyses of genetic
association studies
GBA
HLA-DRB5
BST1 GWAS
GAK
ACMSD Meta-analyses of GWAS
STK39
MCCC1/LAMP3
SYT11
CCDC62/HIP1R
PARK16/1q32
STX1B
GWA 8p22
STBD1
GPNMB
PM20D1
SETD1A
FAM47E
MED13
PD in Asians, including a G2385R polymorphism [61] that
represents one of the most frequent genetic risk factors for
PD in Asian populations, with an estimated OR of 2.2 [52].
3.3. Microtubule-Associated Protein Tau: MAPT. As de-
scribed earlier in this paper, mutations of MAPT cause
frontotemporal dementia with parkinsonism linked to chro-
mosome17(FTDP-17).Moreover,largecase-controlstudies,
meta-analyses of the literature, and GWAS indicate a role for
the MAPT haplotype H1 to disease risk [52, 62, 63].
3.4. Glucocerebrosidase: GBA. Gaucher disease (GD) is an
autosomal recessive lysosomal glycolipid storage disorder
caused by mutations of the GBA gene encoding the enzyme
glucocerebrosidase. A small subset of GD patients develop
parkinsonism [64] and relatives of patients with GD have an
increasedincidenceofparkinsonism[65].Largecohortstud-
ies [66] and recent meta-analyses of the literature revealed
that GBA loss of function variants are the most common ge-
netic risk factor associated with parkinsonism, with an esti-
mated OR of 3.4 for the common GBA N370S variant [52].
Although the mechanism for this association is unknown,
several theories have been proposed, including protein ag-
gregation, lipid accumulation, and impaired autophagy, mi-
tophagy, or traﬃcking [67].
3.5. Additional Loci. The application of GWAS to the under-
standing of the genetics of sporadic PD has signiﬁcantlyThe Scientiﬁc World Journal 5
improved our knowledge in the ﬁeld, and several loci have
been associated with disease risk in recent years. A recent
meta-analysis of published GWAS was performed by the
International Parkinson Disease Genomics Consortium
(IPDGC) for a total of 12,386 PD cases and 21,026 controls
and suggested that, in addition to SNCA, LRRK2, and MAPT
polymorphisms, variants at eight additional loci (HLA-
DRB5, BST1, GAK, ACMSD, STK39, MCCC1/LAMP3,
SYT11, and CCDC62/HIP1R) are signiﬁcantly associated
with disease risk [25]. A more recent two-stage meta-analysis
performed by the IPDGC and the Wellcome Trust Case Con-
trol Consortium 2 (WTCCC2) revealed ﬁve additional loci
associated with PD risk (PARK16/1q32, STX1B, GWA 8p22,
STBD1, GPNMB)[ 68]. Up to date meta-analyses are avail-
able also at the PDGene database for each polymorphism
that has been evaluated in at least four independent genetic
association studies. Accessed on October 2011 the PDGene
database contained 886 updated meta-analyses of the lit-
erature, overall suggesting that 18 loci could contribute to
sporadic PD risk, including most of those already described
(SNCA, LRRK2, MAPT, GBA, HLA-DRB5, BST1, GAK,
ACMSD, STK39, MCCC1/LAMP3, SYT11, CCDC62/HIP1R,
GWA 8p22, GPNMB) and additional ones (PM20D1,
SETD1A, FAM47E and MED13)[ 52].
4. Epigeneticsof Parkinson’sDisease
4.1. DNA Methylation. DNA methylation represents one of
the most important epigenetic processes, along with histone
modiﬁcations and mechanisms involving small RNA molec-
ules. Methylation of CpG sequences might induce chromatin
conformational modiﬁcations and inhibit the access of the
transcriptional machinery to gene promoter regions, thus
altering gene expression levels. Therefore, promoter hyper-
methylation is commonly associated with gene silencing and
promoter demethylation with gene expression, even if some
exceptions to this rule are known [69]. Folate, other B vita-
mins (vitamins B6 and B12), and homocysteine (hcy) parti-
cipate in one-carbon metabolism, a complex pathway re-
quired for the production of S-adenosylmethionine (SAM),
the major intracellular methylating agent. DNA methylation
is closely dependent on the DNA methylation potential,
which is referred to as the ratio between SAM and S-adeno-
sylhomocysteine (SAH) levels. DNA methyltransferases
(DNMTs) are the key enzymes for DNA methylation and
catalyzethetransferofamethylgroupfromSAMtocytosine,
thusforming5-methyl-cytosine.Impairedone-carbonmeta-
bolism, altered DNA methylation potential, reduced DNA
methylation levels in the brain, and altered methylation and
expression of several genes were observed in Alzheimer’s
disease (AD) patients, pointing to a role for epigenetic modi-
ﬁcations in the neurodegenerative process [26]. Less studies
have been so far performed in PD subjects; however, there is
indication of impaired one-carbon metabolism in PD as well
as altered DNA methylation potential [70, 71]. Epigenetic
analyses of PD brains revealed that the SNCA gene could be
subjected to epigenetic regulation [72, 73]. In addition, more
recent large-scale studies suggest that other PD-related genes
could be epigenetically modiﬁed in PD brains (Table 4)[ 68].
4.1.1. α-Synuclein. Several lines of evidence, including the
identiﬁcation of families with SNCA locus duplication and
triplication and the association of both promoter and 3 UTR
polymorphisms with sporadic forms, point to a gene-dosage
eﬀect for SNCA in PD pathogenesis [9]. Studies in individ-
uals with alcoholism [74] and in anorexia patients [75]r e -
vealed hypermethylation of the SNCA promoter, suggesting
that the gene could be epigenetically regulated. The analysis
of SNCA alleles in a PD patient heterozygous for the A53T
mutation, the ﬁrst mutation to be implicated in PD patho-
genesis, revealed that SNCA showed monoallelic expression
in this patient, with epigenetic silencing of the mutated allele
due to histone modiﬁcations but not DNA methylation,
and upregulation of the wild-type allele resulting in higher
mRNA levels than in matched control subjects [76]. Others
observed that the methylation of human SNCA intron 1 de-
creases gene expression, while inhibition of DNA methyla-
tion activates SNCA expression. They also observed that
DNA methylation of SNCA intron 1 was reduced in several
brain regions of sporadic PD patients, including the substan-
tianigra,putamen,andcortex,pointingtowardanepigenetic
regulation of SNCA expression in PD [72]. Another research
group identiﬁed an SNCA CpG island in which the methy-
lation status altered along with increased SNCA expression.
Postmortem brain analysis revealed regional nonspeciﬁc
methylation diﬀerences in this CpG region in the anterior
cingulate and putamen among controls and PD subjects;
however, in the substantia nigra of PD individuals, the meth-
ylation of this region was signiﬁcantly decreased [73]. Both
ﬁndings are consistent with previous reports indicating in-
creased SNCA mRNA levels in PD substantia nigra tissue
[77,78].Arecentpapersuggestedthatα-synucleinsequesters
DNA methyltransferase 1 (DNMT1) from the nucleus [79].
DNMT1 is the maintenance DNA methylation enzyme
whichisabundantlyexpressedintheadultbrainandismain-
ly located in the nuclear compartment. The researchers ob-
served a reduction of nuclear DNMT1 levels in human post-
mortem brain samples from PD and from patients with de-
mentia with Lewy bodies (DLBs) as well as in the brains of
α-synuclein transgenic mice models. Furthermore, seques-
tration of DNMT1 in the cytoplasm resulted in global DNA
hypomethylation in human and mouse brains, involving
CpG islands upstream of SNCAand other genes. The nuclear
DNMT1 levels were partially rescued by overexpression of
DNMT1 in neuronal cell cultures and in α-synuclein trans-
genic mice brains. Therefore, the authors suggested that the
association of DNMT1 and α-synuclein might mediate aber-
rant subcellular localization of DNMT1, resulting in epige-
netic modiﬁcations in the brain [79].
4.1.2. Other Genes. In addition to its association with ARJP,
loss of heterozygosity of parkin has been found in several
types of malignant tumors, including ovarian, breast, and
hepatocellular tumors, and abnormal methylation of parkin
promoter was observed in patients with cancer [80]. The
levels of methylation of the parkin gene promoter were re-
vealedinsamplesfromPDpatientswithheterozygousparkin
mutations, PD patients without parkin mutations, and nor-
mal controls. No diﬀerence was observed between the three6 The Scientiﬁc World Journal
Table 4: Epigenetic changes of PD related genes or PD tissues.
Gene Observation Refs
Reduced SNCA methylation in the substantia nigra of PD patients [72, 73]
α-synuclein sequesters DNMT1 from the nucleus resulting in aberrant DNA methylation [79]
SNCA gene silencing mediated by histone modiﬁcations [76]
α-synuclein binds to histones and inhibits histone acetylation [81–83]
α-synuclein (SNCA) Histone deacetylase inhibitors are neuroprotective against α-synuclein mediated
neurotoxicity in PD animal models [82, 84–90]
α-synuclein expression in C. elegans results in down-regulation of genes coding
for histones [91]
miR-10a, -10b, -212, -132, -495 were impaired in presymptomatic α-synuclein
transgenic mice [92]
miR-7 and mir-153 regulates α-synuclein levels [93, 94]
miR-64 and mir-65 and let-7 were co-under-expressed in α-synuclein transgenic
C. elegans [95]
LRRK2 Mutant LRRK2 antagonizes miR-184∗ and let7 in Drosophila PD models [96]
parkin let-7 family miRNAs let-7 were co-under-expressed in parkin transgenic C. elegans [95]
PARK16/1q32, GPNMB, STX1B Aberrant gene methylation observed in post-mortem PD brains [68]
Tissue Observation Refs
PD brains miR-133b was deﬁcient in midbrain from PD patients [97]
PD brains miR-34b/c down-regulation was observed in pre-motor stages of PD and resulted in
altered expression of DJ1 and parkin proteins [98]
PD lymphocytes Altered expression of miR-1, miR-16-2∗, miR-22∗, miR26a2∗, miR29, miR30 [99]
PD leukocytes Altered methylation patterns of subtelomeric regions [100]
groups, suggesting that parkin promoter methylation is un-
likely to play a role in the pathogenesis and development of
PD [101]. The UCHL-1 gene promoter was found to be hy-
permethylated in various types of cancer [102, 103]. How-
ever, the analysis of UCHL-1 promoter methylation in the
frontalcortexofPDpatientsandcontrolsrevealednosigniﬁ-
cant diﬀerences between the groups [104]. In the same study
the authors evaluated the methylation proﬁles of MAPT pro-
moter in the frontal cortex and hippocampus of controls,
Alzheimer’s disease patients, PD patients, and subjects with
other tauopathies and synucleinopathies. No diﬀerences in
thepercentageofCpGmethylationwerefoundbetweencon-
trol and disease samples or among the diﬀerent pathological
entitiesinanyregionanalyzed[104].Anotherstudyreported
methylation diﬀerences in the gene coding for tumor necro-
sisalpha(TNFA)betweenthecortexandthesubstantianigra,
but these diﬀerences were present in PD cases and controls
[105].TheanalysisoftheoriginalChileanfamilywithKufor-
Rakeb syndrome that led to the discovery of the ATP13A2
geneatthePARK9locusalsorevealedthattherewasnosigni-
ﬁcant correlation between DNA methylation of the ATP13A2
promoter region and disease progression [106]. However,
the recent collaborative study of the IPDGC and WTCCC2
on a dataset of post-mortem brain samples assayed for gene
expression (n = 399) and methylation (n = 292), revealed
methylation and expression changes associated with PD risk
variants in PARK16/1q32, GPNMB,a n dSTX1B, suggesting
that the SNCA gene is unlikely to be the only one subjected
to epigenetic regulation in PD brains [68]. In addition,
an aging-associated alteration of subtelomeric methylation
patterns was observed in peripheral leukocytes of Japanese
PD patients that showed fewer short telomeres than healthy
controls. Moreover, short telomeres in PD patients showed a
constantmethylationpattern,whilstanage-relateddemethy-
lation of short telomeres was observed in controls [100].
4.2. Histone Modiﬁcations. Gene expression proﬁles are
modulated not only by promoter methylation but also by the
chromatin state. Indeed, chromatin can exist in a condensate
inactive state (heterochromatin) or in a noncondensate and
transcriptionallyactivestate(euchromatin).Conformational
changes in histone proteins or modiﬁcations of the way in
which DNA wraps around the histone octamer in nucleo-
somes may either alter or facilitate the access of the trans-
criptional machinery to the promoter region of some genes,
leading to gene silencing or activation, respectively. Histone
tail modiﬁcations include acetylation, methylation, phos-
phorylation, ubiquitylation, sumoylation, and other post-
translational modiﬁcations. Histone tail acetylation is asso-
ciated with chromatin relaxation and transcriptional activa-
tion,whiledeacetylationisrelatedtoamorecondensedchro-
matin state and transcriptional repression [107]. Histone
acetyltransferases (HATs) catalyze the acetylation of lysine
residues in histone tails, whereas histone deacetylation is
mediated by histone deacetylases (HDACs). Another fre-
quently studied modiﬁcation of histone tails is methylation
on either lysine or arginine residues mediated by histone
methyltransferases. Methylation of histone tails can be
associated with either condensation or relaxation of the
chromatin structure, since several sites for methylation areThe Scientiﬁc World Journal 7
present on each tail thus allowing several combinations [107,
108]. Little is still known concerning histone modiﬁcations
in PD brains and most of the current knowledge is derived
from studies in cell cultures and animal models of the
disease, such as those induced by mitochondrial toxins, in-
cluding 1-methyl-4-phenylpyridinium (MPP+), paraquat,
and rotenone, or those overexpressing human α-synuclein
(Table 4). However, those studies have revealed that α-synu-
clein interacts with histones and inhibits histone acetyla-
tion [81, 82] and that several histone deacetylase inhibitors
(HDACIs) are neuroprotective against α-synuclein-mediated
toxicity [82, 84–87]. Particularly, studies performed in nigral
neurons of mice exposed to the herbicide paraquat revealed
that α-synuclein translocates into the nucleus and binds with
histones [81]. Studies in Drosophila showed that α-synuclein
mediates neurotoxicity in the nucleus, binds directly to his-
tone H3, and inhibits histone acetylation. The toxicity of α-
synucleinwasrescuedbytheadministrationofHDACIs[82].
The inhibition of the histone deacetylase Sirtuin 2 rescued
α-synuclein-mediated toxicity in several models of PD [84].
In addition valproic acid (VPA) resulted in inhibition of his-
tone deacetylase activity and in an increase of histone H3
acetylation in brain tissues of rats and resulted neuroprotec-
tive in a rat model of PD (obtained with the administration
of the mitochondrial toxin rotenone), counteracting α-synu-
cleintranslocationintothenuclei[85].Studiesinratandhu-
man neuronal cell cultures also revealed that HDACIs pre-
vent MPP+ -mediated cytotoxicity [86]. Neurotoxic pesti-
cides and paraquat were shown to increase histone acety-
lation in mice brains or cell culture models [87, 88], and
additional studies reported protective eﬀects of HDACIs on
dopaminergicneuronsfollowinganeurotoxic-inducedinsult
[89, 90]. A recent study in α-synuclein transgenic mice re-
vealed that α-synuclein negatively regulates protein kinase
Cδ expression to suppress apoptosis in dopaminergic neu-
rons by reducing p300 histone acetyltransferase activity [83].
A genome-wide expression screen was performed in C. ele-
gans overexpressing human α-synuclein, and nine genes that
form histones H1, H2B, and H4 were downregulated [91].
Overall, these studies point to a role for histone modiﬁ-
cations in α-synuclein-mediated as well as environmental-
induced dopaminergic neuronal cell death. Moreover, the
accumulation of misfolded proteins in proteinaceous inclu-
sions termed aggresomes is a cytoprotective response serv-
ing to sequester potentially toxic misfolded proteins and
facilitate their clearance by autophagy. Histone deacetylase
6 (HDAC6) plays a fundamental role in aggresome forma-
tion. HDAC6 is concentrated in Lewy bodies in PD and
dementia with LBs, and the Drosophila histone deacetylase 6
(dHDAC6) was shown to play a critical role in the protection
of dopaminergic neurons and promoted the formation of α-
synuclein inclusions in a Drosophila PD model expressing
human α-synuclein. On the contrary, mutation of dHDAC6
resulted in the accumulation of toxic α-synuclein oligomers
[109]. It was suggested that the accumulation of HDAC6
might be speciﬁc to α-synucleinopathy and that LBs might
representcytoprotectiveresponsestosequestertoxicproteins
[110]. Aggresome formation involves several regulators, in-
cluding HDAC6, parkin, ataxin-3, and ubiquilin-1 [111].
It has been recently shown in neuronal cell cultures that
HDAC6 participates in the degradation of MPP+ induced
aggregates of α-synuclein by regulating the aggresome-auto-
phagy pathway [112].
4.3. RNA-Mediated Epigenetic Mechanisms. MicroRNAs
(miRNAs) are a group of small noncoding RNAs that bind to
the 3  untranslated region (3 UTR) of target mRNAs and
mediate their posttranscriptional regulation leading to either
degradation or translational inhibition, depending on the
degree of sequence complementarity. In 2007 Kim et al.
investigated the role of miRNAs in mammalian midbrain
dopaminergic neurons and identiﬁed an miRNA, miR-133b,
that is speciﬁcally expressed in midbrain dopaminergic neu-
rons and is deﬁcient in midbrain tissue from patients with
PD.miR-133bregulatesthematurationandfunctionofmid-
brain dopaminergic neurons within a negative feedback cir-
cuit that includes the paired-like homeodomain transcrip-
tion factor Pitx3 [97]. Subsequently, others observed that
the FGF20 rs12720208 polymorphism disrupts a binding site
for miR-433, increasing translation of FGF20 in vitro and
in vivo, and suggested that this could represent a risk factor
for PD [113]. However, a recent study failed to conﬁrm the
association between rs12720208 and PD risk, or any eﬀect
of miR-433 variants to PD pathogenesis [114]. MicroRNA
expression analysis in brains of early symptomatic α-synu-
clein(A30P)-transgenic mice showed that the levels of sever-
al miRNAs (miR-10a, -10b, -212, -132, -495) were signiﬁ-
cantly altered. MiR-132 was reported to be highly inducible
by growth factors and to be a key regulator of neurite out-
growth [92]. Others observed that miR-7, which is expressed
mainly in neurons, represses α-synuclein protein levels bind-
ing to α-synuclein mRNA. Further, miR-7 expression de-
creased in MPP+ -induced models of PD in cultured cells
and in mice, thereby contributing to increased α-synuclein
expression [93]. Another study conﬁrmed that mir-7 regu-
lates α-synuclein levels together with mir-153. Both miRNAs
bind speciﬁcally to the 3 -untranslated region of α-synuclein
and downregulate its mRNA and protein levels, with their
eﬀect being additive. They are expressed predominantly in
the brain with a pattern that mirrors synuclein expression
in diﬀerent tissues as well as during neuronal development,
likely playing a tuning role in the amount of α-synuclein
produced [94]. The analysis of C. elegans models of PD
revealed that several miRNAs were underexpressed in those
animals; particularly the family of miR-64 and miR-65 were
co-underexpressed in α-synuclein transgenic animals, and
members of let-7 family co-underexpressed in both α-synu-
clein and parkin strains [95]. A recent study demonstrates
that blood samples can be used as a source of miRNAs asso-
ciated to PD. Six diﬀerentially expressed miRNAs were iden-
tiﬁed. While miR-1, miR-22∗, and miR-29 expression levels
allowed to distinguish nontreated PD patients from healthy
subjects, miR-16-2∗, miR-26a2∗, and miR30a diﬀerentiated
treated from untreated PD patients [99]. A recent miRNA
proﬁling of PD brains identiﬁed early downregulation of
miR-34b/c which modulate mitochondrial function. Partic-
ularly, misregulation of miR-34b/c was detected in premotor8 The Scientiﬁc World Journal
stages (stages 1–3) of the disease, and thus in cases that did
not receive any PD-related treatment during life, and miR-
34b/c downregulation was coupled to a decrease in the ex-
pression of DJ1 and Parkin proteins [98]. Moreover, studies
in Drosophila bearing LRRK2 PD-associated mutations re-
vealed that pathogenic LRRK2 antagonizes let-7 and miR-
184∗,leadingtotheoverproductionoftheE2F1/DPcomplex
involved in cell cycle and survival control [96]. Overall, these
studies indicate microRNA-mediated mechanisms in PD
pathogenesis (Table 4).
5. Conclusions
Several advances have been gained in our understanding of
the genetics of PD since the ﬁrst report [5]o faSNCA gene
mutation causing familial autosomal dominant PD in 1997
(Table 1). Studies on familial recessive forms of the disease
have highlighted a central role for mitochondrial damage,
repair, and turnover in the pathophysiology of the disease,
with parkin, DJ1, PINK1,a n dFBX07, participating in the
same or in similar/overlapping mitochondrial pathways. In
addition, as suggested by Hardy [24], both glucocerebros-
idase and ATP13A2 are lysosomal enzymes, indicating a sec-
ond PD pathway involving lysosomes. In contrast, α-synu-
clein and LRRK2 biology is still poorly understood, despite
that both proteins are central to the disease etiology [24].
Association studies in sporadic cases and the recent applica-
tion of genome-wide technology led to the identiﬁcation of
almost 20 genes that could modify the individual risk for
the idiopathic forms of the disease (Table 3), and additional
genes are expected to be unravelled within the next future.
Public databases, such as the PD mutation database (http://
www.molgen.ua.ac.be/PDmutDB/) and the PDGene data-
base [52], have been created to continuously update the
genetics of either familial or idiopathic forms, respectively.
There is however a growing evidence that, in addition to
genetic mutations, also epigenetic mechanisms could con-
tribute to disease pathogenesis (Table 4). For example, stud-
ies in PD families as well as in sporadic PD cases suggest an
SNCA gene-dosage eﬀect critical to disease pathogenesis, but
there is also indication of upregulated SNCA gene expres-
sion resulting from promoter demethylation in PD brains
[72, 73]. α-Synuclein itself was shown to exert epigenetic
properties, such as histone tail modiﬁcations [81, 82, 84, 85]
and DNMT1 sequestration [79]. In addition, microRNAs
were found to modulate α-synuclein expression [93, 94].
Other genes critical to PD pathogenesis have been found to
be regulated by promoter methylation [68] or RNA-med-
iated mechanisms [98]. For example, a decrease in the
expression of DJ1 and parkin proteins can result from
microRNA-mediated mechanisms in PD brains, ultimately
leading to mitochondrial impairments such as those
caused by parkin or DJ-1 gene mutations [98]. The in-
creasing amount of papers aimed at understanding the
epigenetics of PD has led to a better understanding of the
molecular pathways involved in dopaminergic neuron de-
generation, and several researchers are now working to
understand the therapeutic potentials of epigenetic molec-
ules to counteract age-related neurodegenerative diseases
[115, 116]. Future research in PD should be aimed at under-
standingthecomplexinterplayamonggeneticandepigenetic
biomarkers, lifestyles, and environmental factors, to further
characterize individuals at risk to develop the disease.
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